BeiGene, a Beijing novel cancer drug company, received approval to begin China clinical trials of a PD-1 immuno-oncology drug, BGB-A317, to treat advanced solid tumors. All four of BeiGene’s clinical stage drugs have now been granted approval to conduct China trials. For A317, it is the fifth site for clinical testing (joining Australia, New Zealand, the US and Taiwan). BeiGene believes its PD-1 candidate has high affinity and specificity. Because A317 does not bind the Fc gamma receptor I, BeiGene expects it will engender a stronger immune system response.
